[
    [
        {
            "time": "2018-03-15",
            "original_text": "Mylan NV Could Be Closer to a Breakout Than Most Traders Realize",
            "features": {
                "keywords": [
                    "Mylan",
                    "breakout",
                    "traders"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Mylan NV Could Be Closer to a Breakout Than Most Traders Realize",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-20",
            "original_text": "Gilead Sciences Expects Decline in Earnings in Fiscal 2018",
            "features": {
                "keywords": [
                    "Gilead",
                    "decline",
                    "earnings"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Gilead Sciences Expects Decline in Earnings in Fiscal 2018",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising",
            "features": {
                "keywords": [
                    "Moody's",
                    "stable",
                    "outlook",
                    "global",
                    "pharmaceuticals",
                    "M&A",
                    "event",
                    "risk"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-05",
            "original_text": "Roche Hemophilia Drug Gets Breakthrough Therapy Designation",
            "features": {
                "keywords": [
                    "Roche",
                    "hemophilia",
                    "drug",
                    "breakthrough",
                    "therapy",
                    "designation"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Roche Hemophilia Drug Gets Breakthrough Therapy Designation",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]